<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>中间体 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/zhongjianti/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Tue, 21 Dec 2021 01:43:24 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>中间体 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2020中国医药中间体行业和市场分析</title>
		<link>https://www.yuanzhezixun.com/2020zhongguoyiyaozhongjiantixingyeheshichang/</link>
		
		<dc:creator><![CDATA[Gaowen]]></dc:creator>
		<pubDate>Mon, 02 Nov 2020 02:37:51 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[CDMO模式]]></category>
		<category><![CDATA[CMO业务外包模式]]></category>
		<category><![CDATA[中间体]]></category>
		<category><![CDATA[医药中间体]]></category>
		<category><![CDATA[医药中间体市场规模]]></category>
		<category><![CDATA[医药行业产业链]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/2020zhongguoyiyaozhongjiantixingyeheshichangfenxi/</guid>

					<description><![CDATA[<span style="font-size: large;">从整个产业链看，目前医药中间体仍处于成长期，平均毛利率一般在15-20%，而原料药的平均毛利率在20-25%，再下游的医药制剂平均毛利率更是高达40-50%，显然更下游部分的毛利率显著高于上游部分。</span><div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>中国CMO（医药生产外包服务）行业发展回顾及发展前景预测：2014-2018年CAGR为10%-13%</title>
		<link>https://www.yuanzhezixun.com/zhongguocmoyiyaoshengchanwaibaofuwuxingyefazha/</link>
		
		<dc:creator><![CDATA[Chenfei]]></dc:creator>
		<pubDate>Mon, 08 Apr 2019 16:32:31 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[中间体]]></category>
		<category><![CDATA[医药生产外包服务]]></category>
		<category><![CDATA[原料药]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=18704</guid>

					<description><![CDATA[2017年全球医药市场容量为1.21万亿美元，2012-2017年复合增速为4.7%，预期未来几年至少保持5.1%的增速水平，2021年将达到1.48万亿美元。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
